KOSDAQBiotech & Pharma023910

DaehanPharmaceutical

₩24,750▼ 0.60%2026-11-18 close
Market Cap
₩148.5B
Turnover
₩200M
Volume
8K
Shares out.
6M
PER
6.1×
PBR
0.5×
EPS
₩4,159
Dividend Yield
3.97%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,000 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Up Three Straight Quarters; Profit Rebounds From Trough

DaehanPharmaceutical's revenue has risen for three straight quarters through the third quarter of 2026, but operating profit, though rebounding from the fourth-quarter 2025 trough, remains below the prior-year level.

  1. 1

    Operating profit fell 18.1% to KRW 31.2 billion in 2025, and the 14.9% operating margin was the lowest of the 2022–2025 period.

  2. 2

    Third-quarter 2026 revenue rose 1.5% year on year to KRW 57 billion, while operating profit fell 23.0% to KRW 8.19 billion.

  3. 3

    According to a newsfield report, IV fluid products accounted for KRW 74.1 billion, or 67.7%, of first-half 2026 revenue of KRW 109.3 billion.

  4. 4

    Net income attributable to controlling shareholders fell 35.2% year on year to KRW 5.65 billion in the third quarter of 2026, declining for two consecutive quarters.

  5. 5

    Operating cash flow was KRW 25.6 billion in 2025, the lowest of the 2022–2025 period.

02

Business structure

DaehanPharmaceutical is a pharmaceutical manufacturer that has grown around IV fluids since its founding in 1945, selling mainly to hospitals and clinics in a B2B model.

The company produces IV fluids, sterile injectables such as ampoules and vials, and dialysis solutions at its injectable facility, and also makes OTC drugs and quasi-drugs. Its core products are basic IV fluids such as sterile physiological saline, Hartmann's solution and 10 percent glucose-containing saline.

Armix, a comprehensive amino acid nutrition IV solution, is presented as a product for compounding TPN (total parenteral nutrition). According to a newsfield report, IV fluid products accounted for KRW 74.1 billion, or 67.7%, of KRW 109.3 billion in first-half 2026 revenue.

Older aggregated data based on the third-quarter 2023 report put IV fluids at 76.60% of sales and ampoules and vials at 22.44% (Hitnews). A 2024 media report placed JW Pharmaceutical's share of the domestic IV fluid market at about 50%, with DaehanPharmaceutical second at about 30%.

A 2024 brokerage report noted that IV fluids are designated as drugs subject to supply-shortage management, so manufacturers receive a margin on production cost. The Ansan plant was completed in 2005 and expanded and rebuilt in 2013 to house its IV injectable lines. Because sales are concentrated in IV fluids, hospital admission demand and product mix drive results.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩56.2B₩10.6B18.9%
2025Q4₩51.1B₩3.6B7.0%
2026Q1₩52.7B₩7.9B14.9%
2026Q2₩56.6B₩8.1B14.3%
2026Q3₩57B₩8.2B14.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩184.3B₩33B₩25B17.9%11.1%22.9%
2023₩195.9B₩35.8B₩28.4B18.3%11.5%18.7%
2024₩204.2B₩38.1B₩33.8B18.6%12.2%17.5%
2025₩208.6B₩31.2B₩27.6B14.9%9.2%15.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue rose from KRW 184.3 billion in 2022 to KRW 195.9 billion in 2023 (up 6.3% year on year), KRW 204.2 billion in 2024 (up 4.2%) and KRW 208.6 billion in 2025 (up 2.2%), increasing for three straight years from 2023 through 2025 with the pace of growth narrowing each year.

Operating profit climbed from KRW 33 billion in 2022 to KRW 35.8 billion in 2023 (up 8.6%) and KRW 38.1 billion in 2024 (up 6.4%), making 2024 the largest year of the period. It then dropped to KRW 31.2 billion in 2025, down 18.1% year on year, as the operating margin fell alongside revenue growth.

The operating margin was 17.9% in 2022, 18.3% in 2023, 18.6% in 2024 and 14.9% in 2025, the lowest of the four years. Net income attributable to controlling shareholders peaked at KRW 33.8 billion in 2024 and was KRW 27.6 billion in 2025, down 18.1%.

Net income including non-controlling interests was disclosed at KRW 25 billion, KRW 28.4 billion, KRW 33.8 billion and KRW 27.6 billion for 2022 through 2025. At the end of 2025, total equity was KRW 300.2 billion and total liabilities were KRW 47.4 billion, and the debt ratio fell from 22.9% in 2022 to 15.8% in 2025.

Operating cash flow moved from KRW 38.9 billion in 2023 to KRW 35.6 billion in 2024 and KRW 25.6 billion in 2025, the lowest of the four years.

Quarterly, revenue of KRW 56.2 billion and operating profit of KRW 10.6 billion in the third quarter of 2025 were followed by a trough in the fourth quarter, with revenue of KRW 51.1 billion (down 9.1% quarter on quarter) and operating profit of KRW 3.57 billion (down 66.4%).

Revenue then rose for three consecutive quarters in 2026, to KRW 52.7 billion, KRW 56.6 billion and KRW 57 billion, and operating profit rose over the same stretch to KRW 7.86 billion, KRW 8.08 billion and KRW 8.19 billion.

However, third-quarter 2026 operating profit was down 23.0% year on year, and net income attributable to controlling shareholders peaked at KRW 6.98 billion in the first quarter of 2026 before falling to KRW 6.75 billion and KRW 5.65 billion over the next two quarters.

05

Industry analysis

A 2024 brokerage analysis argued that IV fluids, as basic medicines, see demand rise in line with an aging population and hospital admission days. The same analysis noted that admissions recovered after the endemic phase and rose again in 2023 with a flu season.

Because IV fluids are designated as drugs subject to supply-shortage management, manufacturers receive a margin on production cost and are relatively insulated from price cuts, according to the same report.

A 2024 media report put JW Pharmaceutical at about 50% of the domestic IV fluid market, with DaehanPharmaceutical second at about 30%.

High-value nutrition IV solutions received approval in September 2021, but a 2024 report said their launch had been delayed, so the pace of product-mix upgrades matters for narrowing the share gap.

Across the wider pharmaceutical sector, a 2026 report said the US president had mentioned raising tariffs on Korean-made drugs to 25% in January 2026, adding uncertainty. With a domestic hospital-supply focus, the direct effect of tariffs may be relatively limited.

Separately, after a low-PBR listing, traditional pharmaceutical companies have been discussed as candidates for expanded shareholder returns such as higher dividends and treasury share cancellation.

Structural support from demand and the stability of the regulated cost structure stand out as strengths, while the share gap with the market leader and the speed of new product launches remain weaknesses.

06

Outlook

Company earnings guidance is not covered by the disclosures and reports reviewed for this report. The key operating variable is the share of IV fluid sales, which reached KRW 74.1 billion, or 67.7%, in first-half 2026, so whether this mix holds is the next checkpoint.

On the product side, the TPN nutrition IV line, including Armix, is central to the company's positioning in nutrition solutions. A 2024 report said the high-value three-chamber comprehensive nutrition IV solution, approved in 2021, had a delayed launch, so the timing of its contribution to the sales mix matters.

Third-quarter 2026 revenue rose for three consecutive quarters, but operating profit has not yet recovered to the prior-year level. Whether revenue growth translates into margin recovery is therefore the question for the next periodic report.

In the 2026 annual report, the key figure will be how far the operating margin recovers from 14.9% in 2025.

On the regulatory side, the Ministry of Food and Drug Safety issued a warning on November 13, 2026 for missing the reporting deadline for narcotics handling, with disposition information public until February 12, 2027. Whether the quality and compliance system holds in upcoming quarters is the matter to watch.

On shareholder returns, whether the cash dividend decided at the March 2026 annual general meeting continues at the next one is the checkpoint.

07

Valuation

PER
6.1×
PBR
0.5×
ROE
8.1%
EPS
₩4,159
BPS
₩53,349
Dividend per share
₩1,000

Valuation is more accurately read through the relationship between net assets, earnings trends and dividends than through the share price level. Total equity at the end of 2025 was KRW 300.2 billion against total liabilities of KRW 47.4 billion, so financial capacity appears ample.

Where the price-to-book ratio sits against its own historical range can serve as a gauge of the discount to net assets. A 2026 media report said DaehanPharmaceutical was included among KOSDAQ pharmaceutical stocks on the exchange's low-PBR list published in early November 2026, which had 151 companies.

The same report said dividend expansion and treasury share cancellation have been discussed as responses by traditional pharmaceutical companies. The company decided a cash dividend at its annual general meeting in March 2026.

On earnings, operating profit fell 18.1% in 2025, and third-quarter 2026 operating profit was down 23.0% year on year. How the discount to net assets is read therefore depends on how far the operating margin recovers.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Continuity of revenue recovery

Revenue rose for three consecutive quarters from the first quarter to the third quarter of 2026, to KRW 52.7 billion, KRW 56.6 billion and KRW 57 billion. Third-quarter 2026 revenue was up 1.5% year on year.

According to a newsfield report, IV fluid sales were KRW 74.1 billion, or 67.7%, in first-half 2026, so IV demand is underpinning the revenue recovery.

IV demand and cost-recovery structure

A 2024 brokerage analysis pointed to steady IV demand as the population ages and hospital admission days recover. The same analysis said IV fluids, designated as drugs subject to supply-shortage management, receive a margin on production cost and are less exposed to price cuts. The structure was presented as a factor that limits revenue volatility.

Shareholder-return discussion and dividend

A cash dividend was decided at the annual general meeting in March 2026. A media report said DaehanPharmaceutical was included among KOSDAQ pharmaceutical stocks on the low-PBR list published in early November 2026.

The same coverage said dividend expansion and treasury share cancellation have been discussed as responses by traditional pharmaceutical companies, and the actual scale of returns will be set by board decisions.

09

Bear factors

Margin decline and lower operating profit

Operating profit fell 18.1% to KRW 31.2 billion in 2025, and the operating margin dropped to 14.9%. Third-quarter 2026 operating profit of KRW 8.19 billion was down 23.0% year on year. Revenue growth has not yet translated into profit, which is the main bear point.

Two consecutive quarterly declines in controlling-shareholder net income

Net income attributable to controlling shareholders peaked at KRW 6.98 billion in the first quarter of 2026 and then fell to KRW 6.75 billion and KRW 5.65 billion. The third-quarter figure was down 35.2% year on year. The four-quarter total from the fourth quarter of 2025 through the third quarter of 2026 was KRW 24.5 billion.

Share gap and delayed new product

A 2024 media report put JW Pharmaceutical at about 50% of the domestic IV fluid market and DaehanPharmaceutical at about 30%, a wide gap. The high-value three-chamber comprehensive nutrition IV solution, approved in 2021, was reported to have a delayed launch. Its contribution to narrowing the gap with the leader has not yet become visible in the reported figures.

10

Risk factors

Regulatory and quality risk

The Ministry of Food and Drug Safety issued a warning on November 13, 2026 for missing the deadline to report narcotics handling, with disposition information public until February 12, 2027.

In May 2026 a fine of KRW 134.4 million was imposed over manufacturing and quality-control issues for a sterile physiological saline product. In February 2026 some lots of an OTC cleansing product were recalled over a labeling error.

Policy and tariff risk

A report said the US president mentioned raising tariffs on Korean-made drugs to 25% in January 2026. Because sales are centered on domestic hospital supply, direct exposure may be relatively small.

However, if the policy status of IV fluids or the cost-recovery framework changes, margins could be affected, so any regulatory change is a checkpoint.

Profitability and cash-flow risk

The 2025 operating margin of 14.9% was the lowest of the four years, and operating cash flow fell to KRW 25.6 billion. Third-quarter 2026 operating profit of KRW 8.19 billion was 23.0% below the prior-year quarter.

A 2024 report said the launch of high-value nutrition IV solutions had been delayed, and if new products reach sales slowly, margin recovery could also be delayed.

11

What to watch next

  1. Through February 12, 2027

    This is the period during which the Ministry of Food and Drug Safety's disposition information on the narcotics reporting deadline violation remains public. Whether further quality or regulatory issues emerge after the disposition is the point to check.

  2. End of March 2027

    This is the deadline for submitting the 2026 annual report, which fixes full-year 2026 revenue, operating profit, net income attributable to controlling shareholders and the operating margin. How far the margin recovers from 14.9% in 2025 is the key point to check.

  3. Around the annual general meeting, March 2027

    This is when the dividend for fiscal 2026 is decided. Whether the scale and direction of shareholder returns match the policy discussion that followed the low-PBR listing is the point to check.

  4. May 15, 2027

    This is the deadline for the first-quarter 2027 quarterly report. The trend in quarterly revenue and how operating profit moves relative to KRW 8.19 billion in the third quarter of 2026 are the next checkpoints.

12

Overall view

DaehanPharmaceutical is a domestic manufacturer for hospitals with a high share of IV fluids, and revenue and operating profit both rose from 2022 through 2024.

In 2025 revenue reached KRW 208.6 billion, a third straight annual increase, but the operating margin fell to 14.9% and operating profit dropped to KRW 31.2 billion.

In 2026 revenue rose for three consecutive quarters through the third quarter, and operating profit rose for three consecutive quarters from the fourth-quarter 2025 trough.

However, third-quarter 2026 operating profit was down 23.0% year on year and net income attributable to controlling shareholders declined for two consecutive quarters, so the recovery has not yet reached the 2025-and-earlier level.

Strengths include stable IV-driven demand, a cost-recovery structure tied to its designation as a drug subject to supply-shortage management, and shareholder-return discussion after the low-PBR listing.

Weaknesses include the margin decline, lower cash flow, the regulatory warning and the share gap with the market leader. Valuation is best read through the relationship between net assets, dividends and the pace of earnings recovery, and the reading depends on whether the operating margin recovers.

The next checkpoints are the operating margin in the 2026 annual report, the dividend decision at the March 2027 annual general meeting, and the first-quarter 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. jobkorea.co.kr
  2. newsthevoice.com
  3. investing-for-everyone.com
  4. money2.daishin.com
  5. hitnews.co.kr
  6. saramin.co.kr
  7. newsfield.net
  8. daihan.com
  9. daihan.com
  10. m.news.nate.com
  11. pharmnews.com
  12. news.nate.com
  13. hkn24.com
  14. dkpharm.co.kr
  15. m.news.nate.com
  16. fnnews.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis